Improved immunogenicity of a core-coated tetanus toroid delivery system

被引:48
作者
Tobío, M
Schwendeman, SP
Guo, Y
McIver, J
Langer, R
Alonso, MJ [1 ]
机构
[1] Sch Pharm, Dept Pharm & Pharmaceut Technol, Santiago De Compostela 15706, Spain
[2] Ohio State Univ, Coll Pharm, Dept Pharmaceut & Pharmaceut Chem, Columbus, OH 43210 USA
[3] Massachusetts Biol Labs, Boston, MA 02130 USA
[4] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
关键词
PLGA microencapsulated cores; antigen delivery; immune response;
D O I
10.1016/S0264-410X(99)00313-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A new microparticulate delivery system composed of a stabilizing gelatin/poloxamer microcore surrounded by a PLGA coat was designed to improve the stability of tetanus toroid (TT) encapsulated in PLGA microspheres. Microcores were prepared by a spray-congealing technique and encapsulated within PLGA using an oil-in-oil (o/o) solvent evaporation technique. SEM analysis of the cross-sections of the microcapsules revealed the adequate encapsulation of the cores, showing an intimate contact between the core and the coating. This structure was responsible for an osmotic phenomenon observed in vitro, which led to the release of the encapsulated TT in a short period of time. Nevertheless, it was observed that the release was affected by the presence of the poloxamer in the core: microspheres without poloxamer in the core exhibit a faster release (2 h) than those that incorporate the surfactant (24 h). The in vivo evaluation of this system showed that the encapsulated toroid induced a low but continuous levels of neutralizing antibodies (Nt), whereas those obtained for the control (aluminum phosphate-adsorbed toroid) decreased after reaching the maximum level at 14 weeks. Moreover, the administration of a mixture of encapsulated and adsorbed TT led to significant higher and more prolonged Nt levels than those measured for the adsorbed toroid. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:618 / 622
页数:5
相关论文
共 13 条
[1]   DETERMINANTS OF RELEASE RATE OF TETANUS VACCINE FROM POLYESTER MICROSPHERES [J].
ALONSO, MJ ;
COHEN, S ;
PARK, TG ;
GUPTA, RK ;
SIBER, GR ;
LANGER, R .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :945-953
[2]  
DURAND C, 1992, NOUV DERMATOL, V11, P523
[3]  
Gupta R.K., 1995, VACCINE DESIGN SUBUN, P229
[4]   THE TITRATION OF TETANUS ANTITOXIN .4. STUDIES ON THE SENSITIVITY AND REPRODUCIBILITY OF THE TOXIN NEUTRALIZATION TEST [J].
GUPTA, RK ;
MAHESHWARI, SC ;
SINGH, H .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1985, 13 (02) :143-149
[5]  
Gupta RK, 1998, DEV BIOLOGICALS, V92, P63
[6]   Chronic local tissue reactions, long term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers [J].
Gupta, RK ;
Alroy, J ;
Alonso, MJ ;
Langer, R ;
Siber, GR .
VACCINE, 1997, 15 (16) :1716-1723
[7]  
MEN Y, 1995, VACCINE, V13, P683
[8]   INVIVO TITRATION OF DIPHTHERIA AND TETANUS ANTIBODIES AT SEVERAL LEVELS [J].
RELYVELD, EH .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1977, 5 (01) :45-55
[9]   CONTINUOUS RELEASE OF PROTEINS FROM BIODEGRADABLE MICROCAPSULES AND IN-VIVO EVALUATION OF THEIR POTENTIAL AS A VACCINE ADJUVANT [J].
SAH, H ;
TODDYWALA, R ;
CHIEN, YW .
JOURNAL OF CONTROLLED RELEASE, 1995, 35 (2-3) :137-144
[10]  
Schwendeman SP, 1996, DEV BIOL STAND, V87, P293